Quest Diagnostics (DGX) FCF Margin (2009 - 2026)

Quest Diagnostics has disclosed FCF Margin across 18 years of filings, most recently posting 5.66% for Q1 2026.

• FCF Margin for Q1 2026 came in at 5.66%, down 176.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 11.76% (up 136.0% YoY), and the FY2025 annual result was 12.32%, up 311.0% from the prior year.
• FCF Margin came in at 5.66% for Q1 2026 at Quest Diagnostics, down from 10.94% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 19.89% in Q4 2023 to a low of 1.42% in Q1 2023.
• The 5-year median for FCF Margin is 11.18% (2024), against an average of 10.66%.
• Peak annual rise in FCF Margin reached 1187 bps in 2023, while the deepest fall reached 1739 bps in 2023.
• Quest Diagnostics' FCF Margin stood at 8.02% in 2022, then surged by 148 bps to 19.89% in 2023, then sank by 35 bps to 13.01% in 2024, then fell by 16 bps to 10.94% in 2025, then tumbled by 48 bps to 5.66% in 2026.
• The last three FCF Margin figures came in at 5.66% (Q1 2026), 10.94% (Q4 2025), and 14.88% (Q3 2025), per Business Quant data.